Expert Interview
Discussing the recent part 1b results from the SUMMIT trial evaluating bezuclastinib in iSM (indolent Systemic Mastocytosis) presented at AAAAI
Ticker(s): COGT, BPMCRady Children’s Hospital-San Diego and UC San Diego School of Medicine
Co-Director of the Multidisciplinary Atopic Dermatitis Program and Severe Asthma Program at Rady Children’s Hospital/UCSD and Associate Clinical Professor of Medicine and Pediatrics in Allergy & Immunology at the University of California, San Diego School of Medicine.
Manages 30 severe asthma patients per year (20 of which are treated with biologics)
Specializes in caring for children with severe asthma and immunodeficiencies; President of the San Diego Allergy Society and active editorial board member of IG Living magazine focused on immunodeficiency.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
